Jimenez J F, Seibert R W, Char F, Brown R E, Seibert J J
Am J Pediatr Hematol Oncol. 1981 Spring;3(1):9-15.
Fetal hydantoin syndrome (FHS), a characteristic pattern of altered growth and development, has been well described in recent years in offsprings of epileptic mothers taking phenytoin or other hydantoin anticonvulsants during the gestational period. Recent reports of neuroblastoma in three patients with the FHS further raise the questions of the "oncogenic effect " of hydantoin compounds. A case of melanotic neuroectodermal tumor of infancy (MNTI) has been studied clinically and pathologically including light microscopy, histochemistry, and electron microscopy. This case strengthens the evidence for the teratogenic and oncogenic effects of hydantoin compounds and we believe that it represents the first reported case of FHS associated with MNTI. It would be most important from a clinical standpoint to carefully scrutinize individuals with the FHS for neoplasias. Furthermore, detailed gestational drug history in children with neuroblastoma and other neoplasias should be carefully searched for, with the hope of clarifying the definitive oncogenic effect of hydantoin compounds.
胎儿苯妥英综合征（FHS）是一种生长发育改变的特征性模式，近年来在妊娠期服用苯妥英或其他乙内酰脲类抗惊厥药的癫痫母亲所生后代中已有详尽描述。最近有报道称，3例FHS患者患有神经母细胞瘤，这进一步引发了关于乙内酰脲类化合物“致癌作用”的问题。本文对1例婴儿黑色素性神经外胚层肿瘤（MNTI）进行了临床和病理研究，包括光学显微镜检查、组织化学检查和电子显微镜检查。该病例进一步证明了乙内酰脲类化合物的致畸和致癌作用，我们认为这是首例报道的与MNTI相关的FHS病例。从临床角度来看，仔细筛查FHS患者是否患有肿瘤至关重要。此外，对于患有神经母细胞瘤和其他肿瘤的儿童，应仔细询问详细的孕期用药史，以期阐明乙内酰脲类化合物的确切致癌作用。
